Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 5Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 903Lung Neoplasms 490Small Cell Lung Carcinoma 140Neoplasms 111Melanoma 107Neoplasm Metastasis 105Breast Neoplasms 99Colorectal Neoplasms 94Ovarian Neoplasms 76Carcinoma, Renal Cell 64Pancreatic Neoplasms 62Squamous Cell Carcinoma of Head and Neck 58Mesothelioma 53Stomach Neoplasms 51Head and Neck Neoplasms 47Adenocarcinoma of Lung 46Triple Negative Breast Neoplasms 45Esophageal Neoplasms 40Colonic Neoplasms 40Brain Neoplasms 40Sarcoma 38Mesothelioma, Malignant 38Prostatic Neoplasms 37Urinary Bladder Neoplasms 36Recurrence 30Carcinoma, Transitional Cell 28Uterine Cervical Neoplasms 25Endometrial Neoplasms 25Carcinoma, Hepatocellular 21Carcinoma, Squamous Cell 19

Interventions

famitinib 1camrelizumab 1aflutinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Advanced NSCLC × Thoracic × Clear all
NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Allist Pharmaceuticals, Inc.

Phase NA Terminated
116 enrolled
Thoracic

Advanced NSCLC

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
1 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡